Onward Therapeutics Raises $28 Million Series B for Cancer Pipeline
Onward Therapeutics raised NT$900 million (~$28 million) in Series B funding to advance its bispecific antibody and NK cell therapy programs, with a Taipei Exchange listing targeted by end-2027.
